Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Elvitegravir | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Elvitegravir | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Elvitegravir | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Elvitegravir | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Elvitegravir | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Elvitegravir | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Elvitegravir | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Elvitegravir | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Elvitegravir | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Elvitegravir | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Elvitegravir | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Elvitegravir | hsa04064 | NF-kappa B signaling pathway | 1.45E-06 | 18 | P10415, Q13489, O00463, Q13546, P14778, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643, Q9UNE0 | BCL2, BIRC3, TRAF5, RIPK1, IL1R1, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB, EDAR | More | | Elvitegravir | hsa04071 | Sphingolipid signaling pathway | 8.69E-05 | 7 | P17252, P21453, Q9H228, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Elvitegravir | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Elvitegravir | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | | Elvitegravir | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | Elvitegravir | hsa04145 | Phagosome | 2.29E-03 | 7 | O75015, Q15080, Q13488, P05164, O60603, P35443, P13765 | FCGR3B, NCF4, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Elvitegravir | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Elvitegravir | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | Elvitegravir | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Elvitegravir | hsa04217 | Necroptosis | 2.93E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Elvitegravir | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | Elvitegravir | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Elvitegravir | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Elvitegravir | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | | Elvitegravir | hsa04613 | Neutrophil extracellular trap formation | 1.63E-04 | 18 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Elvitegravir | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Elvitegravir | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | Elvitegravir | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | Elvitegravir | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Elvitegravir | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | Elvitegravir | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Elvitegravir | hsa04650 | Natural killer cell mediated cytotoxicity | 2.57E-04 | 10 | P19174, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, P26717, P26715 | PLCG1, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | | Elvitegravir | hsa04657 | IL-17 signaling pathway | 4.55E-02 | 5 | O00463, Q16539, P49841, P09341, P14780 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9 | More | | Elvitegravir | hsa04658 | Th1 and Th2 cell differentiation | 7.66E-07 | 12 | Q04759, P07766, P20963, P09693, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Elvitegravir | hsa04659 | Th17 cell differentiation | 8.48E-05 | 11 | Q04759, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Elvitegravir | hsa04660 | T cell receptor signaling pathway | 1.09E-04 | 12 | Q9UDY8, Q04759, P42338, P10747, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239 | MALT1, PRKCQ, PIK3CB, CD28, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | | Elvitegravir | hsa04723 | Retrograde endocannabinoid signaling | 1.75E-02 | 5 | Q14643, P17252, P22694, Q16539, Q16718 | ITPR1, PRKCA, PRKACB, MAPK14, NDUFA5 | More | | Elvitegravir | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Elvitegravir | hsa04912 | GnRH signaling pathway | 3.14E-03 | 5 | P17252, Q16539, Q9Y6R4, Q14643, P22694 | PRKCA, MAPK14, MAP3K4, ITPR1, PRKACB | More | | Elvitegravir | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Elvitegravir | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Elvitegravir | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Elvitegravir | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.10E-03 | 5 | Q14643, P22694, P23771, P17252, P10415 | ITPR1, PRKACB, GATA3, PRKCA, BCL2 | More | | Elvitegravir | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Elvitegravir | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | Elvitegravir | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Elvitegravir | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.96E-04 | 6 | Q16539, P09341, P19875, P19174, P25024, P25025 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Elvitegravir | hsa05132 | Salmonella infection | 9.85E-03 | 4 | Q13546, Q13489, O60282, P68371 | RIPK1, BIRC3, KIF5C, TUBB2C | More | | Elvitegravir | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Elvitegravir | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | | Elvitegravir | hsa05146 | Amoebiasis | 5.70E-05 | 9 | P09341, P19875, P14778, P27930, O60603, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TLR2, PIK3CB, ITGAM, ARG1, ACTN1 | More | | Elvitegravir | hsa05152 | Tuberculosis | 1.26E-02 | 8 | Q13488, O75015, P48382, O60603, P10415, P13765, Q9UDY8, Q16539 | TCIRG1, FCGR3B, RFX5, TLR2, BCL2, HLA-DOB, MALT1, MAPK14 | More | | Elvitegravir | hsa05163 | Human cytomegalovirus infection | 3.64E-02 | 7 | Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Elvitegravir | hsa05202 | Transcriptional misregulation in cancer | 2.67E-04 | 14 | Q12778, Q15532, Q13315, P41732, P14780, P27930, Q16548, Q13489, O15550, P35226, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, BCL2A1, BIRC3, UTX, BMI1, MPO, ELA2, BCL11B, GADD45A | More | | Elvitegravir | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Elvitegravir | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Elvitegravir | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | Elvitegravir | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Elvitegravir | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Elvitegravir | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.00E-04 | 12 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, O60603, P10747, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14, CD4 | More | | Elvitegravir | hsa05321 | Inflammatory bowel disease | 1.66E-04 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | | Elvitegravir | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Elvitegravir | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Elvitegravir | hsa05332 | Graft-versus-host disease | 1.16E-04 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | | Elvitegravir | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | | |